The Medicine and Healthcare products Regulatory Agency (MHRA) in the UK has released guidance advising those involved in clinical trials on specific issues which may arise as a result of COVID-19.
The MHRA has taken a flexible and pragmatic approach with regard to regulatory requirements for clinical trials during this time but has noted that the first priority should be the safety of trial participants.
This guidance will be updated as the situation changes over time.